PMID- 37596705
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231217
IS  - 1099-081X (Electronic)
IS  - 0142-2782 (Linking)
VI  - 44
IP  - 6
DP  - 2023 Dec
TI  - Influence of Gegenqinlian decoction on pharmacokinetics and pharmacodynamics of 
      saxagliptin in type 2 diabetes mellitus rats.
PG  - 396-405
LID - 10.1002/bdd.2374 [doi]
AB  - Gegenqinlian decoction (GQD) is a classic prescription of traditional Chinese 
      medicine (TCM), which originated from Shanghanlun. The combination of GQD and 
      hypoglycemic drugs (saxagliptin, Sax, metformin) is often used to treat Type 2 
      diabetes mellitus (T2DM) in TCM clinics. However, the herb-drug interactions 
      (HDIs) between GQD and hypoglycemic drugs are still unclear. In order to 
      determine the safety of the combination, we assessed the influences of GQD on the 
      pharmacokinetics and pharmacodynamics of Sax in T2DM rats. The plasma 
      concentration of Sax (5 mg/kg) pretreated with GQD (freeze-dried powder, 
      1.35 g/kg) or not was determined by high-performance liquid chromatography 
      (HPLC), and pharmacokinetics parameters were calculated. The influence of GQD on 
      the pharmacodynamics of Sax was investigated by detecting the levels of weight, 
      (see abbreviations list) OGTT, TC, TG, LDL-C, HDL-C, FBG, FINS, HOMA-IR, QUICKI, 
      AST, ALT, and the liver coefficient. The C(max) , AUC(0-t) ,and AUC(0-infinity) of Sax 
      increased significantly in the combination group whether in normal or T2DM rats. 
      The results of pharmacodynamics showed that the weight of rats in each treatment 
      group increased. FBG, TC, TG, LDL-C, and HOMA-IR decreased, HDL-C, FINS, and 
      QUICKI increased significantly (p < 0.05) compared with the model control group. 
      The result showed that the combination of GQD and Sax could not only improve the 
      hypoglycemic effect but also increase the plasma exposure of Sax. The potential 
      HDIs between GQD and Sax should be taken into consideration in clinics. Moreover, 
      for the complexity of the human compared with experimental animals, as well as 
      genetic differences, the in-depth study should be carried out to assess the 
      uniformity of the pharmacokinetics and pharmacodynamics between rats and humans.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Yu, Chao
AU  - Yu C
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Cui, Mingyu
AU  - Cui M
AUID- ORCID: 0000-0002-5480-3357
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Yin, Yifeng
AU  - Yin Y
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Zhu, Fengmei
AU  - Zhu F
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Sui, Yue
AU  - Sui Y
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Yan, Xueying
AU  - Yan X
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
FAU - Gai, Yingli
AU  - Gai Y
AD  - College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
LA  - eng
GR  - H2015044/National Science Foundation of Heilongjiang Province/
GR  - LH2021H102/National Science Foundation of Heilongjiang Province/
GR  - LH2020H096/National Science Foundation of Heilongjiang Province/
GR  - ZHY2022-117/Heilongjiang provincial administration of traditional Chinese 
      Medicine/
PT  - Journal Article
DEP - 20230818
PL  - England
TA  - Biopharm Drug Dispos
JT  - Biopharmaceutics & drug disposition
JID - 7911226
RN  - 0 (gegenqinlian)
RN  - 9GB927LAJW (saxagliptin)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Cholesterol, LDL/therapeutic use
MH  - *Drugs, Chinese Herbal/pharmacokinetics
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Gegenqinlian decoction
OT  - T2DM
OT  - herb-drug interaction
OT  - pharmacokinetics
OT  - saxagliptin
EDAT- 2023/08/19 11:42
MHDA- 2023/12/04 12:42
CRDT- 2023/08/18 23:45
PHST- 2023/06/30 00:00 [revised]
PHST- 2022/12/07 00:00 [received]
PHST- 2023/07/23 00:00 [accepted]
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/08/19 11:42 [pubmed]
PHST- 2023/08/18 23:45 [entrez]
AID - 10.1002/bdd.2374 [doi]
PST - ppublish
SO  - Biopharm Drug Dispos. 2023 Dec;44(6):396-405. doi: 10.1002/bdd.2374. Epub 2023 
      Aug 18.